Growth Metrics

Novartis Ag (NVS) Net Income towards Common Stockholders (QoQ) (2009 - 2023)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 -24.00%
Sep 30, 2023 443.48%
Jun 30, 2023 -68.06%
Mar 31, 2023 -4.64%
Dec 31, 2022 -38.37%
Sep 30, 2022 -95.19%
Jun 30, 2022 755.29%
Mar 31, 2022 -90.01%
Dec 31, 2021 827.73%
Sep 30, 2021 -89.27%
Jun 30, 2021 1,064.40%
Mar 31, 2021 -89.53%
Dec 31, 2020 712.75%
Sep 30, 2020 -89.21%
Jun 30, 2020 2,786.60%
Mar 31, 2019 -288.46%
Dec 31, 2018 89.92%
Sep 30, 2018 -745.00%
Jun 30, 2018 -31.03%
Mar 31, 2018 -88.69%
Dec 31, 2017 -12.61%
Sep 30, 2017 -74.64%
Jun 30, 2017 342.64%
Mar 31, 2017 -93.21%
Dec 31, 2016 1,358.71%
Sep 30, 2016 -5.71%
Jun 30, 2016 202.70%
Mar 31, 2016 9,150.02%
Dec 31, 2015 -97.59%
Sep 30, 2015 461,111,211.11%
Jun 30, 2015 -103.47%
Mar 31, 2015 154.01%
Dec 31, 2014 -796.38%
Sep 30, 2014 200.00%
Jun 30, 2014 -126.85%
Sep 30, 2013 369.23%
Sep 30, 2012 -10.63%
Jun 30, 2012 14.23%
Mar 31, 2012 -47.25%
Dec 31, 2011 85.34%
Sep 30, 2011 -3.92%
Jun 30, 2011 -21.32%
Mar 31, 2011 41.47%
Dec 31, 2010 -18.45%
Sep 30, 2010 31.77%
Jun 30, 2010 -86.71%
Mar 31, 2010 349,404.95%
Dec 31, 2009 8.60%
Sep 30, 2009 3.33%
Jun 30, 2009 3.45%